STENTiT obtains financial support from MKB Innovatiestimulering Topsectoren Zuid-Nederland (MIT-Zuid). This program will provide funds to conduct a technical and economic feasibility study to develop a regenerative stent for children suffering from congenital heart defects. MIT-Zuid is a program in which the 12 Dutch Provinces, the Ministry of Economic affairs and Climate, the Dutch Topsectors[…]
During the 5th edition of the Gerard and Anton Awards, STENTiT was selected as one of the top 10 most promising start-up companies to watch 2018. With this award, the jury wants to highlight start-ups in the Brainport region that have the potential to become the next Philips. According to the jury, STENTiT is providing[…]
STENTiT will present at this year’s PCR Innovators Day Paris. In a session dedicated to stents and scaffolds, the managing directors will kick-off the programme with their presentation entitled “Stentit – Regenerative stents – Minimally invasive vascular restoration”, highlighting their innovative technological approach and promising first in-vivo data. The presentation is scheduled for 16:55 CEST[…]
On June 28th, STENTiT was awarded first prize in the TERMIS European Business Plan Competition. After 2 intense pre-selection rounds, 5 out of 19 teams eventually made it to the finals and pitched in Davos, Switzerland. STENTiT was chosen as the winner of the competition due to the quality of the pitch, the technological approach[…]
We are very pleased to announce that STENTiT is one of the 5 finalists of the TERMIS-EU Business Plan Competition 2017. On Tuesday 27th of June around 17:15, we will present our business plan live on stage in room “A Davos” in Davos Switzerland. The winners will be announced later on Thursday June 29th. We[…]
This afternoon, dr. Sol Cabrera and dr. Sanders will present STENTiT during the short company presentation session at Biomedica 2017. In the spirit of euregional and international cooperation, the Biomedica Life Sciences Summit will bring together top researchers, innovators, and entrepreneurs from Belgium, Germany, and the Netherlands, and also from all over the globe. Its[…]
STENTiT is proud to announce that it has been selected among the top 10 European companies to participate in one of the largest start-up competitions in tissue engineering and regenerative medicine across Europe, the TERMIS-EU BPC. TERMIS is the world’s leading non-profit forum for academic and industrial developments within the fields of tissue engineering and[…]
STENTiT will present its regenerative stent approach at the Innovation for Health event on the 16th of February in Rotterdam, taking part of the Innovation Pitches afternoon session. Innovation for Health is the Netherlands´ premier conference for key players in Health and Life Sciences. It brings together key players and stakeholders who play decisive parts[…]
The STW Take-Off program has just closed their 5th round. STENTiT is very pleased to announce that its Take-Off Phase II application has been granted. The funding will be used to expand the R&D lines, proceed with translational studies and further grow the business. With this achievement we conclude 2016 which has been a very[…]
During the Dutch Life Sciences conference in Leiden, the founders of STENTiT pitched their business plan to a group of life science investors. Among the candidates, STENTiT was unanimously chosen by the jury as the winner of the Investors Forum. In addition, STENTiT presented the case in front of a large audience during the plenary[…]
The NanoNextNL valorization committee has approved to provide financial support to develop the STENTiT business case. NanoNextNL is the Dutch national research and technology programme for micro and nano technology.
The Venture Challenge is an initiative from LifeSciences@Work, designed for life science researchers with entrepreneurial aspirations. STENTiT was selected as one of the 5 participants after pitching the business case to an experienced jury panel. The aim of the program is to develop an idea into a solid business case during a 10-week educational program[…]